KALEIDO BIOSCIENCES INC (KLDO) Stock Price & Overview
NASDAQ:KLDO • US4833471000
The current stock price of KLDO is 0.29 null. Today KLDO is down by -3.69%. In the past month the price decreased by -81.99%. In the past year, price decreased by -95.54%.
KLDO Key Statistics
- Market Cap
- 12.36M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.16
- Dividend Yield
- N/A
KLDO Stock Performance
KLDO Stock Chart
KLDO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to KLDO. When comparing the yearly performance of all stocks, KLDO is a bad performer in the overall market: 99.96% of all stocks are doing better.
KLDO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KLDO. Both the profitability and financial health of KLDO have multiple concerns.
KLDO Earnings
KLDO Forecast & Estimates
12 analysts have analysed KLDO and the average price target is 11.91 null. This implies a price increase of 4006.38% is expected in the next year compared to the current price of 0.29.
For the next year, analysts expect an EPS growth of 10.24% and a revenue growth -36.87% for KLDO
KLDO Groups
Sector & Classification
KLDO Financial Highlights
Over the last trailing twelve months KLDO reported a non-GAAP Earnings per Share(EPS) of -2.16. The EPS increased by 11.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -8155.92% | ||
| ROA | -180.08% | ||
| ROE | N/A | ||
| Debt/Equity | 0.52 |
KLDO Ownership
KLDO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29.51 | 929.554B | ||
| JNJ | JOHNSON & JOHNSON | 20.63 | 577.341B | ||
| MRK | MERCK & CO. INC. | 21.4 | 288.088B | ||
| PFE | PFIZER INC | 9.01 | 151.297B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.91 | 123.651B | ||
| ZTS | ZOETIS INC | 17.68 | 53.866B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.368B | ||
| VTRS | VIATRIS INC | 5.64 | 16.73B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.21 | 11.892B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.259B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.474B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.46B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 4.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KLDO
Company Profile
Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. The company is headquartered in Bedford, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-02-28. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. The company is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development as prevention of infections caused by multi-drug resistant (MDR) bacteria. Nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers, as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.
Company Info
KALEIDO BIOSCIENCES INC
18 Crosby Dr
Bedford MASSACHUSETTS 98072 US
Employees: 76
Phone: 16176749000.0
KALEIDO BIOSCIENCES INC / KLDO FAQ
Can you describe the business of KALEIDO BIOSCIENCES INC?
Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. The company is headquartered in Bedford, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-02-28. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. The company is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development as prevention of infections caused by multi-drug resistant (MDR) bacteria. Nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers, as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.
What is the stock price of KALEIDO BIOSCIENCES INC today?
The current stock price of KLDO is 0.29 null. The price decreased by -3.69% in the last trading session.
Does KALEIDO BIOSCIENCES INC pay dividends?
KLDO does not pay a dividend.
What is the ChartMill rating of KALEIDO BIOSCIENCES INC stock?
KLDO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is KALEIDO BIOSCIENCES INC (KLDO) stock traded?
KLDO stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of KLDO stock?
KALEIDO BIOSCIENCES INC (KLDO) operates in the Health Care sector and the Pharmaceuticals industry.
What is the expected growth for KLDO stock?
The Revenue of KALEIDO BIOSCIENCES INC (KLDO) is expected to decline by -36.87% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.